The observational study showed delays to diagnosis reduced the chances of identifying pathogens and generally led to poorer outcomes.
A project to use the host response to classify acute respiratory infections has been spun off into a company called Host Response, and is seeking industry partners.
The startup plans to launch research-use diagnostic tests this year and support customers wishing to build custom assays.
The firm showed 98 percent sensitivity and 100 percent specificity across all major HCV genotypes in a recent study.
The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
The system will enable testing direct from a tube of blood using peptide nucleic acids-based methods to improve specificity.
The firm is also working on expanding its CTC capture capabilities beyond epithelial cells and will present multiple myeloma applications at an upcoming conference.
Although other groups have been developing noninvasive prenatal testing using digital PCR, BioCore claims to be the first to offer a test commercially.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.